Purchase this article with an account.
Chirag K. Gupta, Lawrence Y. Ho, David L. Goldenberg, Shalini Yalamanchi, George A. Williams; Combination Intravitreal Bevacizumab and Triamcinolone Acetonide Injections in Treatment of Macular Edema from Central Retinal Vein Occlusion. Invest. Ophthalmol. Vis. Sci. 2011;52(14):4508.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To report our results of same day combination intravitreal bevacizumab and triamcinolone acetonide for macular edema from central retinal vein occlusion.
Retrospective consecutive case series of 11 patients who received same day combination intravitreal triamcinolone acetonide (2mg/0.05ml) and bevacizumab (1.25mg/0.05ml) injections. The frequency of intraocular injections, visual acuity, intraocular pressure (IOP), and central foveal thickness (CFT) were analyzed.
The mean age, number of injections and follow up for the group was 71.6 years (SD 13.90), 5.09 injections (SD 5.83) and 14.64 months (SD 6.80), respectively. The mean initial and final visual acuity was LogMAR 1.08 (SD 0.52) and LogMAR 1.15 (SD 0.67), respectively (p-value = 0.69). The mean initial and final CFT was 519 microns (SD 237) and 427 microns (SD 227), respectively (p-value = 0.31). One patient was a steroid responder and one patient developed noninfectious endophthalmitis.
Combination therapy may be a viable alternative to current treatment strategies. Our clinical outcomes with over a year of mean follow up show that there was a reduced rate of steroid response on IOP and decreased number of total injections when combination injections were used; however, there was no statistical difference in visual acuity or CFT.
This PDF is available to Subscribers Only